- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00094393
Clinical Studies of Progeria
Clinical Investigations Into Hutchison-Gilford Progeria Syndrome
This study will examine children with Hutchinson-Gilford Progeria syndrome, a genetic disease that causes many changes to the body over time, including heart disease, bone changes, hair loss, and joint and skin changes. Often called a "premature aging" disease, progeria does not mimic aging completely. This study will examine which body systems are affected in progeria and how each system is affected over time in order to try to develop new treatments.
Patients with progeria who are between 6 months and 70 years of age and who are able to travel to the NIH in Bethesda, Md., may be eligible for this 5- to 10-year study.
Participants come to the NIH Clinical Center for evaluation every 2 years. Each 4-5 day visit includes the following tests and procedures:
- Medical history and physical examination
- Blood tests to analyze cardiovascular risk factors, blood counts, blood chemistries, and for research
- Urine tests for sugar and proteins
- Photographs to study growth problems
- X-ray studies to determine bone density and body composition, such as body fat and muscle
- Electrocardiogram (EKG) and echocardiogram (heart ultrasound) to study the heart and blood vessels
- Lung function tests to measure energy consumption and lung capacity
- Skin biopsy (surgical removal of a small skin sample) to examine cellular changes
- Hearing tests
- Eye examination to evaluate eyesight, eye pressure and structures of the eye
- Physical therapy evaluation with stretching and exercises to measure how the joints bend and straighten
- Dental examination, including X-rays
- Meeting with a nutritionist who will track the patient's food intake and take body measurements
- Magnetic resonance imaging (MRI) for patients who are old enough to undergo the procedure without sedation. This test uses a magnetic field and radio waves to examine body organs. For this test, the patient must lie still in the scanner, a narrow cylindrical tube.
Patients are provided the results of their medical tests. Information about the patient is submitted to the PRF Cell and Tissue Bank in Peabody, Massachusetts.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
- Inclusion criteria consist of male and female children of all ethnic groups with the diagnosis of HGPS.
- An individual in whom a clinical diagnosis of HGPS has been
verified by Dr. Gordon will be eligible for this protocol.
EXCLUSION CRITERIA:
- Exclusion criteria consist of patients below 6 months and over 70 years of age. Another exclusion is the inability to travel to the NIH due to advanced cardiovascular disease, as reflected by unstable angina, congestive heart failure, or other serious symptoms.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
Collaborators and Investigators
Publications and helpful links
General Publications
- DeBusk FL. The Hutchinson-Gilford progeria syndrome. Report of 4 cases and review of the literature. J Pediatr. 1972 Apr;80(4):697-724. doi: 10.1016/s0022-3476(72)80229-4. No abstract available.
- Pesce K, Rothe MJ. The premature aging syndromes. Clin Dermatol. 1996 Mar-Apr;14(2):161-70. doi: 10.1016/0738-081x(95)00151-5. No abstract available.
- Badame AJ. Progeria. Arch Dermatol. 1989 Apr;125(4):540-4.
- Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO 3rd, Gahl WA, Introne WJ. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008 Feb 7;358(6):592-604. doi: 10.1056/NEJMoa0706898.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 050004
- 05-HG-0004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Progeria
-
Bundang CHA HospitalCompletedHutchinson-Gilford Progeria SyndromeKorea, Republic of
-
Assistance Publique Hopitaux De MarseilleCompletedHutchinson-Gilford Progeria SyndromeFrance
-
PRG Science & Technology Co., Ltd.Amarex Clinical ResearchCompletedHutchinson-Gilford Progeria Syndrome | Werner SyndromeUnited States
-
Boston Children's HospitalEnrolling by invitation
-
Eiger BioPharmaceuticalsApproved for marketing
-
Boston Children's HospitalMerck Sharp & Dohme LLC; Schering-Plough; Eiger BioPharmaceuticalsActive, not recruitingProgeriaUnited States
-
Boston Children's HospitalDana-Farber Cancer Institute; Brigham and Women's Hospital; Schering-PloughCompletedProgeria | Hutchinson-Gilford SyndromeUnited States
-
Monica E. KleinmanSchering-PloughCompletedProgeria | Hutchinson-Gilford SyndromeUnited States
-
Centre Hospitalier Universitaire DijonNot yet recruitingKosaki Overgrowth Syndrome | Penttinen SyndromeFrance